Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 53Brain Neoplasms 51Carcinoma, Non-Small-Cell Lung 49Lung Neoplasms 30Neoplasm Metastasis 29Breast Neoplasms 23Pancreatic Neoplasms 16Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Hepatocellular 13Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Kidney Neoplasms 5Liver Neoplasms 4Glioblastoma 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Spinal Cord Neoplasms 3Sarcoma 3Prostate Cancer Metastatic 3NSCLC 3Meningioma 3Lymphatic Metastasis 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

testosterone 17 beta-cypionate 1pembrolizumab 1palbociclib 1enfortumab vedotin 1Urinary Diversion 1Therapeutics 1Testosterone Propionate 1Standard of Care 1Radiosurgery 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Mitomycin 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Health Information Exchange 1Gemcitabine 1Fluorouracil 1Cystectomy 1Cisplatin 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Diseases × Radiosurgery × 1 year × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡